SCHEMBL7077297

SCHEMBL7077297

O=C(CC(=O)c1cn(Cc2ccccn2)cn1)c1cccc(Cc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 6/20 0.54
▸ KDM5A P29375 2/20 0.44
▸ KDM5B Q9UGL1 2/20 0.44
▸ KDM4A O75164 2/20 0.42
▸ CYP19A1 P11511 2/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ GPR132 Q9UNW8 1/20 0.38
▸ PTPN1 P18031 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CTNNB1 P35222 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ KLKB1 P03952 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7084804 0.86 KDM4C (0.50) KDM4CKDM5AKDM5BKDM4ACYP19A1
SCHEMBL7081681 0.84 CYP2E1 (0.48) KDM4CKDM5AKDM5BKDM4ACYP19A1
SCHEMBL7077600 0.79 PTPN1 (0.42) KDM4CKDM5AKDM5BPTPN1KDM4E
SCHEMBL7129471 0.79 KMT2A (0.43) KDM4CKDM5AKDM5BALDH1A1SIGMAR1
SCHEMBL7550388 0.78 KDM4C (0.39) KDM4CCYP19A1BRD4GPR132PTPN1
SCHEMBL7078797 0.76 SIRT2 (0.40) KDM4CKDM5AKDM5BPTPN1KDM4E
SCHEMBL7130008 0.76 KDM2B (0.42) KDM4CKDM5AKDM5BKDM4AKDM4E
SCHEMBL7077241 0.74 CTNNB1 (0.51) PTPN1KDM4EALDH1A1CYP1A2CYP2C19
SCHEMBL7077275 0.73 KDM2B (0.40) KDM5AKDM5BALDH1A1POLB
SCHEMBL7085191 0.73 KDM2B (0.43) KDM4CALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 — — US claimed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 — — EP claimed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 — — EP claimed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 — — WO claimed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 — — US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 — — EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 — — EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 KDM4C 1486/4885KDM5A 2332/4885KDM5B 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback